Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 596

Sort by

Sort Order Select

Journal Articles

Integrated multidisciplinary approaches to improve prognosis prediction in multiple myeloma

Claudio Cerchione, Nour Alassi, Sarah Tassinari, Delia Cangini, Sofia Cortesi, Michela Ceccolini, Davide Nappi, Sonia Ronconi, Alessandra Merlotti, Daniel Remondini, Giacomo Feliciani, Alice Rossi, Gerardo Musuraca, Nicola Normanno, Giorgia Simonetti, Giovanni Martinelli, Matteo Marchesini

Blood (2025) 146 (Supplement 1): 2140.

https://doi.org/10.1182/blood-2025-2140

Published: 2025

Journal Articles

Unveiling FLT3 in B-ALL: Molecular drivers and targeted treatment opportunities

Blood (2025) 146 (Supplement 1): 5148.

https://doi.org/10.1182/blood-2025-5148

Published: 2025

Journal Articles

Different kinetic behavior of molecular reduction by BCR::ABL1 transcript types in frontline treatment of chronic myeloid leukemia patients: A GIMEMA labnet CML network database survey.

Blood (2025) 146 (Supplement 1): 3755.

https://doi.org/10.1182/blood-2025-3755

Published: 2025

Journal Articles

Apcin-derived CDC20 inhibitors synergize with microtubule disruptors to induce mitotic catastrophe in acute leukemias

Andrea Marranci, Gabriele Micheletti, Francesco Olimpico, Roberta Napolitano, Martina Ghetti, Lorenzo Ledda, Samantha Bruno, Giovanni Martinelli, Carla Boga, Andrea Ghelli Luserna di Rorà, Giorgia Simonetti

Blood (2025) 146 (Supplement 1): 1717.

https://doi.org/10.1182/blood-2025-1717

Published: 2025

Journal Articles

NPM1 and IDH1/2 mutations show limited prognostic impact in relapsed AML: Evidence from the avalon cohort

Blood (2025) 146 (Supplement 1): 6967.

https://doi.org/10.1182/blood-2025-6967

Published: 2025

Journal Articles

Multiple Myeloma and Smoldering Myeloma: Prospective Evaluation of 3 T Whole Body MRI and 18F-FDG PET/CT and Their Impact on Clinical Management

Claudio Cerchione, Davide Bezzi, Davide Nappi, Matteo Marchesini, Andrea Prochowski Iamurri, Paola Caroli, Arrigo Cattabriga, Delia Cangini, Giacomo Feliciani, Emiliano Loi, Federica Matteucci, Domenico Barone, Sonia Ronconi, Michela Ceccolini, Gerardo Musuraca, Nicola Normanno, Giovanni Martinelli, Alice Rossi

Blood (2024) 144 (Supplement 1): 3326.

https://doi.org/10.1182/blood-2024-211380

Published: 2024

Journal Articles

Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations

Christian Recher, Jenny O'Nions, Ibrahim Aldoss, Ana Alfonso Pierola, Alicia Allred, Juan Manuel Alonso-Dominguez, Laura Barreyro, Pierre Bories, Martin Curtis, Nikki Daskalakis, Matteo Giovanni Della Porta, Hartmut Döhner, Amber D'Souza, James P. Dugan, Jordi Esteve Reyner, Matthew Exum, Amir T. Fathi, Pasquale L. Fedele, Lucille Ferrante, Stan Gaj, Sylvain Garciaz, Ana Garrido, Sara Garrido Paniagua, Christina Guttke, Emmanuel Gyan, Brett Hiebert, Elias Jabbour, Madlen Jentzsch, Hagop M. Kantarjian, Marina Konopleva, Jan Krönke, Min Chul Kwon, Christina Loefgren, Oliver Lomas, Valentina Mancini, Ioannis Mantzaris, Giovanni Martinelli, Daniel Morillo Giles, Joseph Murphy, Kathryn Packman, Cristina Papayannidis, Ulrike Philippar, Uwe Platzbecker, Sravanti Rangaraju, Christoph Röllig, Olga Salamero, Madhu Sanga, Tim Sauer, Emma Searle, Natalia Tovar, Trevor Tucker, Nicolas Vallet, Lachlin Vaughan, Gala Vega, Paresh Vyas, Andrew Wei

Blood (2024) 144 (Supplement 1): 215.

https://doi.org/10.1182/blood-2024-207072

Published: 2024

Journal Articles

Molecular Outcome of Chronic Myeloid Leukemia Affected Patients Not in Deep Molecular Response: The “Others” from the Gimema Labnet Network

Blood (2024) 144 (Supplement 1): 992.

https://doi.org/10.1182/blood-2024-210201

Published: 2024

Journal Articles

Centralized MRD Assessment in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax Combined with Intensified FLAI Chemotherapy (V-FLAI) As Induction Therapy of Non Low-Risk AML

Blood (2024) 144 (Supplement 1): 1574.

https://doi.org/10.1182/blood-2024-198139

Published: 2024

Journal Articles

Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2891.

https://doi.org/10.1182/blood-2024-207842

Published: 2024

Journal Articles

Combining Gene Expression Profiling and Integrated Multidisciplinary Approaches to Improve Prognosis Prediction in Multiple Myeloma

Claudio Cerchione, Nour Alassi, Davide Nappi, Chiara Servili, Emanuela Scarpi, Delia Cangini, Sonia Ronconi, Michela Ceccolini, Matteo Paganelli, Luigi Coppola, Giacomo Feliciani, Alice Rossi, Fabiana Mammoli, Nicola Normanno, Gerardo Musuraca, Giorgia Simonetti, Giovanni Martinelli, Matteo Marchesini

Blood (2024) 144 (Supplement 1): 6838.

https://doi.org/10.1182/blood-2024-203211

Published: 2024

Journal Articles

Impact-AML: A European Project for Optimizing Treatment and Assessing Quality of Life in Relapsed/Refractory Acute Myeloid Leukemia Patients

Antonio Maturo, Elisa Castellaccio, Veronica Moretti, Samantha Nier, Giovanni Martinelli, Giovanni Marconi, Gerardo Musuraca, Simone Adelsbach, Martina Vittoria Minguzzi, Maria Belles Esteller

Blood (2024) 144 (Supplement 1): 7651.

https://doi.org/10.1182/blood-2024-206970

Published: 2024

Journal Articles

Investigating Phosphoinositide-Related and Apoptotic Pathways in Azacitidine and Venetoclax Combination Therapy in Higher-Risk Myelodysplastic Neoplasms and Leukemic Cell Lines

Irene Casalin, Eleonora Ceneri, Alessia De Stefano, Alessandra Cappellini, Andrea Pellagatti, Jacqueline Boultwood, Michele Cavo, Stefano Ratti, Lucia Manzoli, Lucio Cocco, Anna Ferrari, Giorgia Simonetti, Giovanni Martinelli, Miriam Fogli, Stefania Paolini, Sarah Parisi, Antonio Curti, Carlo Finelli, Matilde Yung Follo

Blood (2024) 144 (Supplement 1): 6686.

https://doi.org/10.1182/blood-2024-200842

Published: 2024

Journal Articles

Radiopsy, Quantitative Wb-Mri Adc and Fat Fraction Sequences for Discrimination of Smoldering Multiple Myeloma and Multiple Myeloma: A Prospective Observational Study

Claudio Cerchione, Alice Rossi, Paola Caroli, Matteo Marchesini, Federica Matteucci, Delia Cangini, Domenico Barone, Davide Nappi, Davide Bezzi, Anna Sarnelli, Giovanni Martinelli, Nicola Normanno, Giacomo Feliciani

Blood (2024) 144 (Supplement 1): 4725.

https://doi.org/10.1182/blood-2024-210734

Published: 2024

Journal Articles

Profiling Baseline Health-Related Quality of Life of Patients with Newly Diagnosed Myeloid Malignancies: A Pooled Analysis of 3349 Patients with AML, APL and MDS from the International Proactive Project

Fabio Efficace, Adriano Venditti, Thomas Baldi, Joanna Canham, Giovanni Martinelli, Alfonso Piciocchi, Mike Dennis, Steve Knapper, Nigel H. Russell, Sean Johnson, Maria Teresa Voso, Marco Vignetti, Ian Thomas

Blood (2024) 144 (Supplement 1): 407.

https://doi.org/10.1182/blood-2024-204588

Published: 2024

Journal Articles

Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel

Nicola Gökbuget, Nicolas Boissel, Sabina Chiaretti, Hervé Dombret, Michael Doubek, Adele Fielding, Robin Foà, Sebastian Giebel, Dieter Hoelzer, Mathilde Hunault, David I. Marks, Giovanni Martinelli, Oliver Ottmann, Anita Rijneveld, Philippe Rousselot, Josep Ribera, Renato Bassan

Blood (2024) 143 (19): 1891–1902.

https://doi.org/10.1182/blood.2023020794

Published: 2024

Includes: Supplemental data

Journal Articles

Management of ALL in adults: 2024 ELN recommendations from a European expert panel

Blood (2024) 143 (19): 1903–1930.

https://doi.org/10.1182/blood.2023023568

Published: 2024

Includes: Supplemental data

Journal Articles

Pre-Existing Myeloid Subclones May Account for a Subset of Acute Myeloid Leukemias and Myelodysplastic Neoplasms in Patients with Pre-Existing or Contemporary Lymphoid Disorders

Agnese Mattei, Giovanni Marconi, Sonia Ronconi, Delia Cangini, Michela Ceccolini, Claudio Cerchione, Irene Zacheo, Maria Benedetta Giannini, Marianna Norata, Giovanni Martinelli, Anna Ferrari, Maria Teresa Bochicchio, Martina Ghetti, Matteo Marchesini, Giorgia Simonetti, Gerardo Musuraca, Davide Nappi

Blood (2023) 142 (Supplement 1): 1475.

https://doi.org/10.1182/blood-2023-186760

Published: 2023

Journal Articles

Final Analysis for the Primary End-Point of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1536.

https://doi.org/10.1182/blood-2023-184678

Published: 2023

Journal Articles

Impact-AML: A European Master Framework for Cohort Studies and Pragmatic Clinical Trials in Relapse or Refractory Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1533.

https://doi.org/10.1182/blood-2023-184745

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Integrated multidisciplinary approaches to improve prognosis prediction in multiple myeloma

Unveiling FLT3 in B-ALL: Molecular drivers and targeted treatment opportunities

Different kinetic behavior of molecular reduction by BCR::ABL1 transcript types in frontline treatment of chronic myeloid leukemia patients: A GIMEMA labnet CML network database survey.

Apcin-derived CDC20 inhibitors synergize with microtubule disruptors to induce mitotic catastrophe in acute leukemias

NPM1 and IDH1/2 mutations show limited prognostic impact in relapsed AML: Evidence from the avalon cohort

Multiple Myeloma and Smoldering Myeloma: Prospective Evaluation of 3 T Whole Body MRI and 18F-FDG PET/CT and Their Impact on Clinical Management

Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations

Molecular Outcome of Chronic Myeloid Leukemia Affected Patients Not in Deep Molecular Response: The “Others” from the Gimema Labnet Network

Centralized MRD Assessment in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax Combined with Intensified FLAI Chemotherapy (V-FLAI) As Induction Therapy of Non Low-Risk AML

Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Combining Gene Expression Profiling and Integrated Multidisciplinary Approaches to Improve Prognosis Prediction in Multiple Myeloma

Impact-AML: A European Project for Optimizing Treatment and Assessing Quality of Life in Relapsed/Refractory Acute Myeloid Leukemia Patients

Investigating Phosphoinositide-Related and Apoptotic Pathways in Azacitidine and Venetoclax Combination Therapy in Higher-Risk Myelodysplastic Neoplasms and Leukemic Cell Lines

Radiopsy, Quantitative Wb-Mri Adc and Fat Fraction Sequences for Discrimination of Smoldering Multiple Myeloma and Multiple Myeloma: A Prospective Observational Study

Profiling Baseline Health-Related Quality of Life of Patients with Newly Diagnosed Myeloid Malignancies: A Pooled Analysis of 3349 Patients with AML, APL and MDS from the International Proactive Project

Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel

Management of ALL in adults: 2024 ELN recommendations from a European expert panel

Pre-Existing Myeloid Subclones May Account for a Subset of Acute Myeloid Leukemias and Myelodysplastic Neoplasms in Patients with Pre-Existing or Contemporary Lymphoid Disorders

Final Analysis for the Primary End-Point of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Impact-AML: A European Master Framework for Cohort Studies and Pragmatic Clinical Trials in Relapse or Refractory Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only